Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Early Phase 1

1(20.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 1(2)

Early Phase 1(1)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06622057Phase 3Not Yet Recruiting

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Role: lead

NCT05065957Phase 2Recruiting

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Role: lead

NCT03531320Phase 1Completed

Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase

Role: lead

NCT01800630Phase 1Completed

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Role: lead

NCT01678690Early Phase 1Completed

An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

Role: lead

All 5 trials loaded